Who are Heparin 50U/ml's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Control - UFH.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/heparin-50u-ml.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Heparin 50U/ml — Competitive Intelligence Brief

Heparin 50U/ml (Heparin 50U/ml) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant (unfractionated heparin). Area: Cardiovascular.

marketed Anticoagulant (unfractionated heparin) Antithrombin III (indirect mechanism); Thrombin and Factor Xa (downstream targets) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Heparin 50U/ml (Heparin 50U/ml) — University of Florence. Heparin is an anticoagulant that inhibits blood clotting by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Heparin 50U/ml TARGET	Heparin 50U/ml	University of Florence	marketed	Anticoagulant (unfractionated heparin)	Antithrombin III (indirect mechanism); Thrombin and Factor Xa (downstream targets)
Control - UFH	Control - UFH	GlaxoSmithKline	phase 3	Anticoagulant (unfractionated heparin)	Antithrombin III (enhancer); Factors IIa, Xa, and other serine proteases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant (unfractionated heparin) class)

GlaxoSmithKline · 1 drug in this class
University of Florence · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Heparin 50U/ml — Competitive Intelligence Brief. https://druglandscape.com/ci/heparin-50u-ml. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab